Q-omics provides the consensus-scored HTR3D profile across patient tissues and cancer cell-line models. HTR3D expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, HTR3D is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, HTR3D RNA expression shows 6,413 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, KIRC, and STAD as cancer lineages where HTR3D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR3D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR3D survival associations across molecular data types. HTR3D RNA expression shows survival associations in the most cancer types (10), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR3D RNA expression–survival associations across cancer types. High HTR3D expression shows unfavorable associations in BRCA, COAD, ACC, KIRC, STAD and LIHC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for HTR3D RNA expression.
This table summarizes HTR3D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HTR3D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR3D shows lower tumor expression in KIRC, KICH and BRCA. The KIRC box plot shows higher HTR3D RNA expression in normal versus tumor tissue (log2 FC = −0.166, t-test p < 0.001).
This table shows molecular features associated with HTR3D in patient tissues and cancer cell lines. In patient samples, HTR3D shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR3D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
